1. Design, synthesis and biological evaluation of naphthyl amide derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors.
- Author
-
Yu Q, Song C, Bi L, Zhao S, Lei Q, Yang N, Chen H, Wang Y, He Y, and Deng H
- Subjects
- Humans, Structure-Activity Relationship, Cell Line, Tumor, Molecular Structure, Drug Screening Assays, Antitumor, Naphthalenes pharmacology, Naphthalenes chemical synthesis, Naphthalenes chemistry, Dose-Response Relationship, Drug, Molecular Docking Simulation, Monoacylglycerol Lipases antagonists & inhibitors, Monoacylglycerol Lipases metabolism, Drug Design, Enzyme Inhibitors pharmacology, Enzyme Inhibitors chemical synthesis, Enzyme Inhibitors chemistry, Amides chemistry, Amides pharmacology, Amides chemical synthesis, Cell Proliferation drug effects, Antineoplastic Agents pharmacology, Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry
- Abstract
Monoacylglycerol lipase (MAGL) is a key enzyme responsible for the metabolism of the endocannabinoid 2-arachidonoylglycerol (2-AG), and has attracted great interest due to its involvement in various physiological and pathological processes, such as cancer progression. In the past, a number of covalent irreversible inhibitors have been reported for MAGL, however, experimental evidence highlighted some drawbacks associated with the use of these irreversible agents. Therefore, efforts were mainly focused on the development of reversible MAGL inhibitor in recent years. Here, we designed and synthesized a series of naphthyl amide derivatives (12-39) as another type of reversible MAGL inhibitors, exemplified by ± 34, which displayed good MAGL inhibition with a pIC
50 of 7.1, and the potency and selectivity against endogenous MAGL were further demonstrated by competitive ABPP. Moreover, the compound showed appreciable antiproliferative activities against several cancer cells, including H460, HT29, CT-26, Huh7 and HCCLM-3. The investigations culminated in the discovery of the naphthyl amide derivative ± 34, and it may represent as a new scaffold for MAGL inhibitor development, particularly for the reversible ones., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF